Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

RAHWAY, N.J.--(BUSINESS WIRE) September 11, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin signaling inhibitor...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials